Lauren is Vice President, Clinical Development and Clinical Pharmacology at ReForma Therapeutics, bringing over 10 years of pharmaceutical industry experience in clinical pharmacology and drug development. She specializes in quantitative clinical pharmacology and model-informed drug development, integrating pharmacokinetic, pharmacodynamic, and modeling approaches to guide clinical development strategy, evaluate formulation changes, and inform regulatory decision-making.

Prior to joining ReForma, Lauren held clinical pharmacology leadership positions at small and mid-sized pharmaceutical companies, where she led clinical pharmacology strategy across drug development programs. Her experience spans early- and late-stage development, with particular expertise in bioavailability and bioequivalence, formulation bridging, pharmacokinetic comparability across formulations and dosing regimens, dose selection, population pharmacokinetics, exposure-response modeling, and drug-drug interactions. She has supported programs through clinical development, regulatory submissions, and product approvals.

Lauren is also the founder of L3 Clin Pharm LLC and holds a Ph.D. from Duke University. She brings a quantitative, data-driven approach to complex drug development challenges, translating clinical pharmacology data into actionable development strategies.